FOUNDATIONONE® LIQUID CDx

PATIENT
Chang, Wei-Wei

TUMOR TYPE
Unknown primary adenocarcinoma

COUNTRY CODE
TW

REPORT DATE
22 Nov 2021

ORDERED TEST #
ORD-1240190-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT

DISEASE Unknown primary adenocarcinoma
NAME Chang, Wei-Wei
DATE OF BIRTH 02 July 1981
SEX Female
MEDICAL RECORD # 47543986

PHYSICIAN

ORDERING PHYSICIAN Chen, Ming-Huang
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN

SPECIMEN ID WWC 7/2/1981
SPECIMEN TYPE Blood
DATE OF COLLECTION 10 November 2021
SPECIMEN RECEIVED 15 November 2021

Biomarker Findings

Blood Tumor Mutational Burden - 0 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Cannot Be Determined

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

KRAS A146V
GNAS R201H
MUTYH splice site 892-2A>G
TET2 Q232*

0 Therapies with Clinical Benefit
0 Therapies with Resistance
10 Clinical Trials

BIOMARKER FINDINGS
Blood Tumor Mutational Burden - 0 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Cannot Be Determined

THERAPY AND CLINICAL TRIAL IMPLICATIONS
No therapies or clinical trials. See Biomarker Findings section
MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).
Tumor fraction is an estimate of the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample based on observed aneuploid instability.

GENOMIC FINDINGS		VAF %
KRAS -	A146V	1.3%
10 Trials see p. 7		

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
None	None

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING IN SELECT CANCER SUSCEPTIBILITY GENES

Findings below have been previously reported as pathogenic germline in the ClinVar genomic database and were detected at an allele frequency of >30%. See appendix for details.

MUTYH - splice site 892-2A>G ..... p. 6

This report does not indicate whether variants listed above are germline or somatic in this patient. In the appropriate clinical context, follow-up germline testing would be needed to determine whether a finding is germline or somatic.

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

TET2 - Q232* ..... p. 6

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

GNAS - R201H ..... p. 5

MUTYH - splice site 892-2A>G ..... p. 6

TET2 - Q232* ..... p. 6

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531



HISTORIC PATIENT FINDINGS		ORD-1240190-01 VAF%
Blood Tumor Mutational Burden		0 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Cannot Be Determined
KRAS	● A146V	1.3%
GNAS	● R201H	0.30%
MUTYH	● splice site 892-2A>G	50.8%
TET2	● Q232*	3.0%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT
0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-2] and anti-PD-1[3] therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb[1]. In HNSCC, a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[4].

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)[5-7]. Published data investigating the prognostic implications of TMB have mainly been investigated in the context of tissue TMB. In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis[8], as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high-TMB samples each), but not BRAF (10.3%) or KRAS (9.4%)[9]. Although some studies have reported a lack of association between smoking and increased TMB in NSCLC[8,10], several other large studies did find a strong link[11-14]. In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations[15-16] and with microsatellite instability (MSI)[16], which in turn has been reported to correlate with better prognosis[17-24]. Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma[25-28] and bladder cancer[29], it is also linked with improved prognosis in patients with these tumor types[26].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[30-31] and cigarette smoke in lung cancer[32-33], treatment with temozolomide-based chemotherapy in glioma[34-35], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[15,26,36-38], and microsatellite instability (MSI)[15,26,38]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-3]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT
Cannot Be Determined

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with high tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results[39]. However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[40-45].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[46]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[47], Ewing sarcoma and osteosarcoma[48], prostate cancer[43], breast cancer[49], leiomyosarcoma[50], esophageal cancer[51], colorectal cancer[52], and gastrointestinal cancer[53].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[54], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[55-56]. However, the tumor fraction estimate in this sample could not be determined with confidence.

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
KRAS

ALTERATION
A146V

TRANSCRIPT ID
NM_004985

CODING SEQUENCE EFFECT
437C>T

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors[57-58]. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations[59]. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer[60]. Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib[61-66]. Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors[67-68]. Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations[69-70]. While clinical responses have been reported for patients with KRAS-mutated ovarian[71-74], cervical small cell neuroendocrine[75], or uterine cancer[73] treated with MEK inhibitor monotherapy, multiple clinical trials have not demonstrated increased response rates for patients with KRAS-altered tumors including KRAS-mutated CRC[76-79], pancreatic cancer[80-82], and NSCLC[77,83-84]. A Phase 2 study of trametinib and uprosertib for patients with recurrent cervical cancer reported no responses for patients with KRAS-mutated (2/2 SDs) or KRAS-amplified (1/1 SD) cancer[85]. Clinical responses have been reported for combination treatment strategies including MEK inhibitors with PI3K or AKT inhibitors for patients with KRAS-mutated ovarian cancer[86-88] and KRAS-mutated endometrioid adenocarcinoma[89].

FREQUENCY & PROGNOSIS

KRAS mutations have been observed in 18% of tumor samples analyzed in the COSMIC database, including 53% of pancreatic, 45% of peritoneal, 32% of colorectal, 21% of small intestinal, 18% of biliary tract, and 15% of lung tumors (Jul 2021)[7]. Mutations in KRAS have been reported in 32-54% of colorectal cancer cases, with the G12C, G12V, and G13D mutations specifically identified in 7-11%, 26-32%, and 16-24% of cases, respectively[90-95]. Additionally, an activating KRAS mutation has been reported in more than 80% of pancreatic adenocarcinomas, with the majority of mutations found at codon 12[96-99]. KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma[97]. KRAS mutation in lung adenocarcinoma has been correlated with disease progression, poorly differentiated tumors, and aggressive tumor behavior (NCCN NSCLC Guidelines, v4.2021)[100-102]. However, the prognostic value of KRAS mutation in lung adenocarcinoma may differ among ethnic groups and may depend upon the specific allelic variant present[103].

FINDING SUMMARY

KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation[62,104]. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, R68S, and K117N have been characterized as activating and oncogenic[62,105-127].

GENE
GNAS

ALTERATION
R201H

TRANSCRIPT ID
NM_000516

CODING SEQUENCE EFFECT
602G>A

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies targeted to GNAS mutation in cancer. However, there is limited data indicating that a patient with appendiceal adenocarcinoma and a GNAS mutation (R201H) benefited from trametinib for 4 months[128]. Additionally, a patient with GNAS-mutated Erdheim-Chester disease exhibited a PR following treatment with single-agent trametinib[129].

FREQUENCY & PROGNOSIS

The highest incidences of GNAS mutations have been reported in intraductal papillary mucinous neoplasms (40-66%)[130-131] and appendiceal mucinous neoplasms (50-72%)[132-133] as well as in tumors affecting the peritoneum (22%), pituitary gland (20%), bone (15%), pancreas (12%), and small intestine (12%)(COSMIC, 2021)[7]. Amplification of GNAS has been reported in ovarian epithelial carcinomas (12-30%)[134-136], colorectal adenocarcinoma (9%)[15], stomach adenocarcinoma (7%)[137], lung adenocarcinoma (6.5%)[138], breast invasive carcinoma (6.5%)[139], pancreatic adenocarcinoma (6%)[140], and sarcomas (5.8%)[141]. GNAS mutations are rare in hematological malignancies generally (COSMIC, 2021)[7,142-143]. Activating GNAS mutations have been identified in gastrointestinal polyps in 75% (3/4) of patients with McCune-Albright syndrome[144]. Amplification of GNAS has been associated with shorter progression-free survival in patients with ovarian cancer[135-136], while activating GNAS mutations have been correlated with tumor progression and poor prognosis in patients with gastric cancer[145].

FINDING SUMMARY

GNAS encodes the alpha subunit of the stimulatory G protein (Gs-alpha)[146]. Gs-alpha is a guanine-nucleotide binding protein (G protein) that is involved in hormonal regulation of adenylate cyclase[146]. GNAS has been reported to be amplified in cancer[6] and may be biologically relevant in this context[147-148]. GNAS alterations that have been shown to result in constitutive activation of adenylyl cyclase and an increase in cellular cAMP concentration[149-154] are predicted to be activating. Mutations at R201 specifically are commonly associated with McCune-Albright syndrome, a disease that can co-occur with various cancers in patients with GNAS activating mutations[155-157].

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
MUTYH

ALTERATION
splice site 892-2A>G

TRANSCRIPT ID
NM_001048171

CODING SEQUENCE EFFECT
892-2A>G

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies or clinical trials available to address MUTYH alterations in cancer.

FREQUENCY & PROGNOSIS

In general, somatic MUTYH mutations are infrequently reported across cancer types (COSMIC, 2021)[7]. Monoallelic MUTYH mutation occurs in 1-2% of the general population[158-159]. There is conflicting data regarding the impact of monoallelic mutations on the risk of developing CRC[160-162]. Patients with MUTYH-mutant CRC were reported to have significantly improved overall survival compared to patients without MUTYH mutation[163].

FINDING SUMMARY

MUTYH (also known as MYH) encodes an enzyme involved in DNA base excision repair, and loss of function mutations in MUTYH result in increased rates of mutagenesis and promotion of tumorigenesis[164]. The two most frequently reported MUTYH loss of function mutations are G382D (also referred to as G396D) and Y165C (also referred to as Y179C)[158-159,165-167]. Numerous other MUTYH mutations have also been shown to result in loss of function[165-168].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the MUTYH variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with MUTYH-associated polyposis (ClinVar, Sep 2021)[169]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline biallelic MUTYH mutation causes MUTYH-associated polyposis (also known as MYH-associated polyposis or MAP), an autosomal recessive condition characterized by multiple colorectal adenomas and increased lifetime risk of colorectal cancer (CRC)[158,170-172]. MAP accounts for approximately 0.7% of all CRC cases and 2% of early-onset CRC cases[158]. In contrast to CRC, the role of MUTYH mutation in the context of other cancer types is not well established[173-177]. Estimates for the prevalence of MAP in the general population range from 1:5,000-1:10,000[159]. Therefore, in the appropriate clinical context, germline testing of MUTYH is recommended.

GENE
TET2

ALTERATION
Q232*

TRANSCRIPT ID
NM_001127208

CODING SEQUENCE EFFECT
694C>T

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in TET2 in solid tumors.

FREQUENCY & PROGNOSIS

TET2 alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Jan 2021)[5-6]. Published data investigating the prognostic implications of TET2 alterations in solid tumors are limited (PubMed, Jan 2021).

FINDING SUMMARY

TET2 encodes a tumor suppressor involved in reversing DNA methylation marks, a process critical for proper gene regulation[178-179]. Alterations such as seen here may disrupt TET2 function or expression[180-184].

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[185-190]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[185-186]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[191]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[189,192-193]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
KRAS

ALTERATION
A146V

RATIONALE
KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK

LOCATIONS: Guangzhou (China)

NCT03498521

PHASE 2

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

TARGETS
ALK, RET, SMO, AKTs, PARP, PD-L1, EGFR, VEGFA, MEK, BRAF, ERBB2, ERBB3, ROS1, TRKA, TRKB, TRKC

LOCATIONS: Fukuoka (Japan), Ehime (Japan), Seoul (Korea, Republic of), Aichi (Japan), Tokyo (Japan), Chiba (Japan), Bangkok (Thailand), Blacktown (Australia), St Leonards (Australia), Helsinki (Finland)

NCT03989115

PHASE 1/2

Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors

TARGETS
SHP2, MEK

LOCATIONS: Seoul (Korea, Republic of), Oregon, California, Colorado, Arizona, Wisconsin, Illinois

NCT03284502

PHASE 1

Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors

TARGETS
MEK, RAFs

LOCATIONS: Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of)

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03905148

PHASE 1/2

Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Patients With Advanced or Refractory Solid Tumors

TARGETS
RAFs, EGFR, MEK

LOCATIONS: Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas

NCT02079740

PHASE 1/2

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

TARGETS
BCL-W, BCL-XL, BCL2, MEK

LOCATIONS: Massachusetts

NCT04111458

PHASE 1

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

TARGETS
KRAS, SOS1, MEK

LOCATIONS: Frankfurt am Main (Germany), Köln (Germany), Utrecht (Netherlands), Rotterdam (Netherlands), Massachusetts, Tennessee, Texas, North Carolina

NCT02407509

PHASE 1

Phase I Trial of RO5126766

TARGETS
RAFs, MEK, mTOR

LOCATIONS: London (United Kingdom), Sutton (United Kingdom)

NCT04800822

PHASE 1

PF-07284892 in Participants With Advanced Solid Tumors

TARGETS
SHP2, ROS1, ALK, BRAF, EGFR, MEK

LOCATIONS: California, Michigan, New York, Tennessee, Texas

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ARID1A
V1982I

DDR1
R649W

IRS2
A512T

KMT2A (MLL)
I3186T

MSH3
A58V

POLE
R1839C

PTCH1
R1303C

SPEN
G1286W

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*C11orf30* (EMSY)	*C17orf39* (GID4)	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*
CCND1	*CCND2*	*CCND3*	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*
CD274 **(PD-L1)**	*CDC73*	***CDH1***	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*
CDKN2A	*CDKN2B*	*CDKN2C*	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***
CSF1R	*CSF3R*	*CTCF*	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*
DAXX	*DDR1*	***DDR2*** **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15**, 24-27**	*EP300*
EPHA3	*EPHB1*	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***
ESR1 **Exons 4-8**	*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FAM46C*	*FANCA*
FANCC	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*
FGF23	*FGF3*	*FGF4*	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*
FLCN	*FLT1*	***FLT3*** **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*
GNA11 **Exons 4, 5**	*GNA13*	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3F3A*	*HDAC1*	*HGF*
HNF1A	***HRAS*** **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*
INPP4B	*IRF2*	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*
KDM5C	*KDM6A*	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

KRAS	*LTK*	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*
MAPK1	*MCL1*	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***
MITF	*MKNK1*	*MLH1*	***MPL*** **Exon 10**	*MRE11A*	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*
MTAP	***MTOR*** **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*
NF1	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**
NRAS **Exons 2, 3**	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**
PDGFRB **Exons 12-21, 23**	*PDK1*	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TERC** ncRNA	***TERT**** **Promoter**	*TET2*
TGFBR2	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*	*TYRO3*
U2AF1	***VEGFA***	*VHL*	*WHSC1*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status

Blood Tumor Mutational Burden (bTMB)

Tumor Fraction

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from observed aneuploid instability in the sample.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.
11. Alterations reported may include somatic (not

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.

12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.1.1

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
4. Li et al., 2020; ASCO Abstract 6511
5. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
6. Gao J, et al. Sci Signal (2013) pmid: 23550210
7. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
8. Xiao D, et al. Oncotarget (2016) pmid: 27009843
9. Spigel et al., 2016; ASCO Abstract 9017
10. Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269
11. Govindan R, et al. Cell (2012) pmid: 22980976
12. Ding L, et al. Nature (2008) pmid: 18948947
13. Imielinski M, et al. Cell (2012) pmid: 22980975
14. Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028
15. Nature (2012) pmid: 22810696
16. Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117
17. Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541
18. Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368
19. Brueckl WM, et al. Anticancer Res. () pmid: 12820457
20. Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476
21. Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274
22. Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542
23. Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535
24. Laghi L, et al. Dig Dis (2012) pmid: 22722556
25. Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395
26. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
27. Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778
28. Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559
29. Cazier JB, et al. Nat Commun (2014) pmid: 24777035
30. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
31. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
32. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
33. Rizvi NA, et al. Science (2015) pmid: 25765070
34. Johnson BE, et al. Science (2014) pmid: 24336570
35. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
36. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
37. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
38. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
39. Li et al., 2021; AACR Abstract 2231
40. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
41. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
42. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
43. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
44. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
45. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
46. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
47. Lapin M, et al. J Transl Med (2018) pmid: 30400802
48. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
49. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
50. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
51. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
52. Fan G, et al. PLoS ONE (2017) pmid: 28187169
53. Vu et al., 2020; DOI: 10.1200/PO.19.00204
54. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
55. Zhang EW, et al. Cancer (2020) pmid: 32757294
56. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
57. Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384
58. Mainardi S, et al. Nat Med (2018) pmid: 29808006
59. Koczywas et al., 2021; AACR Abstract LB001
60. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
61. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174
62. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
63. Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318
64. Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367
65. Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089
66. Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556
67. Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722
68. Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843
69. Hofmann et al., 2021; AACR Abstract CT210
70. Gort et al., 2020; ASCO Abstract TPS3651
71. Monk BJ, et al. J Clin Oncol (2020) pmid: 32822286
72. Farley J, et al. Lancet Oncol. (2013) pmid: 23261356
73. Slosberg ED, et al. Oncotarget (2018) pmid: 29765547
74. Han C, et al. Gynecol Oncol Rep (2018) pmid: 29946554
75. Lyons YA, et al. Gynecol Oncol Rep (2014) pmid: 26075998
76. Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291
77. Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927
78. Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139
79. Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733
80. Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152
81. Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778
82. Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206
83. Blumenschein GR, et al. Ann. Oncol. (2015) pmid: 25722381
84. Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668
85. Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140
86. Spreafico et al., 2014; ASCO Abstract 5506
87. Juric et al., 2014; ASCO Abstract 9051
88. Banerji et al., 2014; ASCO Abstract e13559
89. Shapiro GI, et al. Invest New Drugs (2019) pmid: 31020608
90. Lièvre A, et al. Cancer Res. (2006) pmid: 16618717
91. De Roock W, et al. Lancet Oncol. (2011) pmid: 21163703
92. Huang CW, et al. BMC Cancer (2013) pmid: 24330663
93. Kosmidou V, et al. Hum. Mutat. (2014) pmid: 24352906
94. Maus MK, et al. Lung Cancer (2014) pmid: 24331409
95. Peeters M, et al. J. Clin. Oncol. (2013) pmid: 23182985
96. Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196
97. Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280
98. Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602
99. Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325
100. Yip PY, et al. J Thorac Oncol (2013) pmid: 23392229
101. Rekhtman N, et al. Mod. Pathol. (2013) pmid: 23619604
102. Scoccianti C, et al. Eur. Respir. J. (2012) pmid: 22267755
103. Curr Opin Oncol (2014) pmid: 24463346
104. Kahn S, et al. Anticancer Res. () pmid: 3310850
105. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185
106. Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068
107. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
108. Sci. STKE (2004) pmid: 15367757
109. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
110. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
111. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
112. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
113. Kim E, et al. Cancer Discov (2016) pmid: 27147599
114. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
115. Naguib A, et al. J Mol Signal (2011) pmid: 21371307
116. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
117. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
118. Scheffzek K, et al. Science (1997) pmid: 9219684
119. Scholl C, et al. Cell (2009) pmid: 19490892
120. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
121. Tyner JW, et al. Blood (2009) pmid: 19075190
122. Valencia A, et al. Biochemistry (1991) pmid: 2029511
123. White Y, et al. Nat Commun (2016) pmid: 26854029
124. Wiest JS, et al. Oncogene (1994) pmid: 8058307
125. Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513
126. Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870
127. Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033
128. Ang C, et al. Case Rep Oncol () pmid: 28868010
129. Saunders IM, et al. Oncologist (2019) pmid: 31740567
130. Furukawa T, et al. Sci Rep (2011) pmid: 22355676
131. Wu J, et al. Sci Transl Med (2011) pmid: 21775669
132. Nishikawa G, et al. Br. J. Cancer (2013) pmid: 23403822
133. Singhi AD, et al. Hum. Pathol. (2014) pmid: 24925222
134. Nature (2011) pmid: 21720365
135. Kan Z, et al. Nature (2010) pmid: 20668451
136. Tominaga E, et al. Gynecol. Oncol. (2010) pmid: 20537689
137. Nature (2014) pmid: 25079317
138. Nature (2014) pmid: 25079552
139. Nature (2012) pmid: 23000897
140. Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536
141. Barretina J, et al. Nat. Genet. (2010) pmid: 20601955
142. Lohr JG, et al. Cancer Cell (2014) pmid: 24434212
143. Chapman MA, et al. Nature (2011) pmid: 21430775
144. Zacharin M, et al. J. Med. Genet. (2011) pmid: 21357941
145. Alakus H, et al. World J. Gastroenterol. (2009) pmid: 20027678
146. Hayward BE, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9860993
147. Zack TI, et al. Nat. Genet. (2013) pmid: 24071852
148. Beroukhim R, et al. Nature (2010) pmid: 20164920
149. Masters SB, et al. J. Biol. Chem. (1989) pmid: 2549064
150. Graziano MP, et al. J. Biol. Chem. (1989) pmid: 2549065
151. Jang IS, et al. Exp. Mol. Med. (2001) pmid: 11322485
152. Landis CA, et al. Nature (1989) pmid: 2549426
153. Tobar-Rubin R, et al. J. Mol. Endocrinol. (2013) pmid: 23288949
154. Mariot V, et al. Bone (2011) pmid: 20887824
155. Weinstein LS, et al. N. Engl. J. Med. (1991) pmid: 1944469
156. Collins MT, et al. J. Clin. Endocrinol. Metab. (2003) pmid: 12970318

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

157. Nault JC, et al. J. Hepatol. (2012) pmid: 21835143
158. Hegde M, et al. Genet. Med. (2014) pmid: 24310308
159. Aretz S, et al. Eur. J. Hum. Genet. (2013) pmid: 22872101
160. Win AK, et al. Gastroenterology (2014) pmid: 24444654
161. Lubbe SJ, et al. J. Clin. Oncol. (2009) pmid: 19620482
162. Jones N, et al. Gastroenterology (2009) pmid: 19394335
163. Nielsen M, et al. J. Natl. Cancer Inst. (2010) pmid: 21044966
164. David SS, et al. Nature (2007) pmid: 17581577
165. Molatore S, et al. Hum. Mutat. (2010) pmid: 19953527
166. Kundu S, et al. DNA Repair (Amst.) (2009) pmid: 19836313
167. D'Agostino VG, et al. DNA Repair (Amst.) (2010) pmid: 20418187
168. Ali M, et al. Gastroenterology (2008) pmid: 18534194
169. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
170. Sampson JR, et al. Lancet (2003) pmid: 12853198
171. Sieber OM, et al. N. Engl. J. Med. (2003) pmid: 12606733
172. Al-Tassan N, et al. Nat. Genet. (2002) pmid: 11818965
173. Rennert G, et al. Cancer (2012) pmid: 21952991
174. Zhang Y, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16492928
175. von der Thüsen JH, et al. J. Clin. Oncol. (2011) pmid: 21189386
176. Casper M, et al. Fam. Cancer (2014) pmid: 24420788
177. Smith LM, et al. Pancreatology (2009) pmid: 20110747
178. Ito S, et al. Nature (2010) pmid: 20639862
179. Guo JU, et al. Cell (2011) pmid: 21496894
180. Iyer LM, et al. Cell Cycle (2009) pmid: 19411852
181. Ko M, et al. Nature (2010) pmid: 21057493
182. Yang H, et al. Oncogene (2013) pmid: 22391558
183. Hu L, et al. Cell (2013) pmid: 24315485
184. Wang Y, et al. Mol. Cell (2015) pmid: 25601757
185. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
186. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
187. Xie M, et al. Nat. Med. (2014) pmid: 25326804
188. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
189. Severson EA, et al. Blood (2018) pmid: 29678827
190. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
191. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
192. Chabon JJ, et al. Nature (2020) pmid: 32269342
193. Razavi P, et al. Nat. Med. (2019) pmid: 31768066

Electronically signed by Julie Tse, M.D. | 22 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531